Top

Published in:

Open Access 01-12-2012 | Review

Therapeutic advancement of chronic lymphocytic leukemia

Authors: Kang Lu, Xin Wang

Published in: Journal of Hematology & Oncology | Issue 1/2012

Abstract

Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This article reviews the ongoing clinical advances in the treatment of CLL in both previously untreated and relapsed disease and focuses on the benefit of different therapeutic strategies, the most effective therapy combinations and the potential activity of novel agents. Novel agents and combination therapies have been investigated by several studies in both the upfront and relapsed setting, particularly for patients with 17p deletion, TP53 mutation and fludarabine-refractory CLL. While these agents and combination therapies have improved initial response rates, ongoing studies are continued to determine and improve the efficacy and safety. Despite advancements in the treatment of CLL have led to high response rates, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option and reduced-intensity conditioning (RIC) allo-HSCT must be strongly considered whenever feasible. As such, ongoing studies of these agents and other novel approaches in clinical development are needed to expand and improve treatment options for CLL patients.

Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet. 2008, 371: 1017-1029. 10.1016/S0140-6736(08)60456-0.PubMedCrossRef

Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010, 10: 37-50.PubMed

Maddocks KJ, Lin TS: Update in the management of chronic lymphocytic leukemia. J Hematol Oncol. 2009, 2: 29-10.1186/1756-8722-2-29.PubMedCentralPubMedCrossRef

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000, 343: 1750-1757. 10.1056/NEJM200012143432402.PubMedCrossRef

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009, 114: 3382-3391. 10.1182/blood-2009-02-206185.PubMedCrossRef

Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008, 14: 309-317. 10.1158/1078-0432.CCR-07-1061.PubMedCrossRef

Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009, 27: 4378-4384. 10.1200/JCO.2008.20.8389.PubMedCrossRef

Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey GT: Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients > =70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab. ASH Annual Meeting Abstracts. 2011, 118: 3914-

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006, 107: 885-891.PubMedCrossRef

10.

Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007, 370: 230-239. 10.1016/S0140-6736(07)61125-8.PubMedCrossRef

11.

Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007, 25: 793-798. 10.1200/JCO.2006.08.0762.PubMedCrossRef

12.

Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A, Goede V, Wendtner CM, Lichter P, Emmerich B: Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG. ASH Annual Meeting Abstracts. 2089, 2008: 112-

13.

Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M: Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010, 28: 1863-1869. 10.1200/JCO.2009.25.9630.PubMedCrossRef

14.

Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M: Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006, 108: 473-479. 10.1182/blood-2005-12-4828.PubMedCrossRef

15.

Robak T, Blonski J, Jamroziak K, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J: Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study. ASH Annual Meeting Abstracts. 2011, 118: 3915-

16.

Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003, 101: 6-14. 10.1182/blood-2002-04-1258.PubMedCrossRef

17.

Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011, 29: 1349-1355. 10.1200/JCO.2010.31.1811.PubMedCentralPubMedCrossRef

18.

Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007, 109: 405-411. 10.1182/blood-2006-07-033274.PubMedCentralPubMedCrossRef

19.

Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD: Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 2010, 116: 2180-2187.PubMedCentralPubMed

20.

Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L: A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2012, 30: 1232-1240. 10.1007/s10637-011-9737-y.PubMedCrossRef

21.

Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S: A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL. ASH Annual Meeting Abstracts. 2011, 118: 3901-

22.

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Koppler H: Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas Achieves High Response Rates. ASH Annual Meeting Abstracts. 2011, 118: 1615-

23.

Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Gonzalez M, Ferra C, Abella E, Delgado J, Garcia-Marco JA: Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). ASH Annual Meeting Abstracts. 2011, 118: 293-

24.

Jenke P, Eichhorst B, Busch R, Anheier N, Duehrsen U, Duerig J, Dreyling MH, Bergmann M, Goebeler ME, Hurtz HJ: Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. ASH Annual Meeting Abstracts. 2011, 118: 2860-

25.

Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007, 25: 5616-5623. 10.1200/JCO.2007.12.9098.PubMedCrossRef

26.

Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L: An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2012, 156: 481-489. 10.1111/j.1365-2141.2011.08965.x.PubMedCrossRef

27.

Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A: Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012, 53: 424-429. 10.3109/10428194.2011.623258.PubMedCrossRef

28.

Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Winkler D, Buhler A, Zenz T, Mack S, Busch R, Hinke A: Alemtuzumab Plus Oral Dexamethasone. Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. ASH Annual Meeting Abstracts. 2011, 118: 2854-

29.

Geisler CH, van 't Veer MM, van Putten W, Jurlander J, Walewski J, Tjonnfjord G, Itala-Remes M, Kimby E, Kozak T, Polliack A: Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial. ASH Annual Meeting Abstracts. 2011, 118: 290-

30.

Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011, 118: 2085-2093. 10.1182/blood-2011-03-341032.PubMedCentralPubMedCrossRef

31.

Zent CS, LaPlant BR, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay N, Weiner GJ, Witzig TE: Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). ASH Annual Meeting Abstracts. 2011, 118: 1790-

32.

Delmer A, Tournilhac O, Lepretre S, Cazin B, Feugier P, Dreyfus B, Mahe B, Leporrier M, Michallet A-S, Jaccard A: Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM. ASH Annual Meeting Abstracts. 2011, 118: 3900-

33.

Castro JE, Ariza-Serrano LM, Barajas-Gamboa JS, Diaz-Perez JA, James DF, Ale-Ali A, Kipps TJ: Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2011, 118: 2866-

34.

Jones JA, Stark A, Zhao W, Lin TS, Rai KR, Marcucci G, Peterson B, Larson RA, Heerema NA, Byrd JC: Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. ASH Annual Meeting Abstracts. 2011, 118: 1791-

35.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010, 28: 1749-1755. 10.1200/JCO.2009.25.3187.PubMedCrossRef

36.

Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Trneny M: Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 921-

37.

Flinn IW, Harwin WN, Macias-Perez IM, Tucker PS, Waterhouse DM, Papish SW, Jones JA, Hainsworth JD, Byrd JC: A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ASH Annual Meeting Abstracts. 2011, 118: 3912-

38.

Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011, 117: 6450-6458. 10.1182/blood-2010-12-323980.PubMedCrossRef

39.

Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, Tun H, Bowen DA, Jelinek DF, Hanson CA, Kay N: Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL. ASH Annual Meeting Abstracts. 2011, 118: 3898-

40.

Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007, 13: 4448-4455. 10.1158/1078-0432.CCR-06-1463.PubMedCrossRef

41.

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S: Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010, 115: 489-495. 10.1182/blood-2009-08-237727.PubMedCentralPubMedCrossRef

42.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC: The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010, 116: 3705-3714. 10.1182/blood-2010-04-001230.PubMedCentralPubMedCrossRef

43.

Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, Gerdes C, Nopora A: Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction. ASH Annual Meeting Abstracts. 2006, 108: 229-

44.

Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J: Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011, 186: 3762-3769. 10.4049/jimmunol.1000303.PubMedCrossRef

45.

Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, Tilly H, Weisser M, Birkett J, Salles GA: Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2009, 114: 884-

46.

Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA: Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011, 118: 2970-2975. 10.1182/blood-2011-04-348896.PubMedCentralPubMedCrossRef

47.

Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A: Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012, 87: 66-68. 10.1002/ajh.22233.PubMedCrossRef

48.

Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A: Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009, 2: 36-10.1186/1756-8722-2-36.PubMedCentralPubMedCrossRef

49.

Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011, 118: 3489-3498. 10.1182/blood-2011-03-339077.PubMedCentralPubMedCrossRef

50.

James DF, Brown JR, Werner L, Wierda WG, Barrientos JC, Castro J, Greaves A, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ: Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. ASH Annual Meeting Abstracts. 2011, 118: 291-

51.

Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A: Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 980-

52.

Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L: Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. ASH Annual Meeting Abstracts. 2011, 118: 1788-

53.

Shanafelt TD, Tun H, Hanson CA, Zent CS, Leis JF, Call TG, LaPlant BR, Bowen D, Pavey ES, Jelinek DF, Kay N: Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. ASH Annual Meeting Abstracts. 2011, 118: 3899-

54.

Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang S, Lerner S, Ferrajoli A: Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. ASH Annual Meeting Abstracts. 2011, 118: 3907-

55.

Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D: Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol. 1995, 93: 73-79. 10.1159/000204115.PubMedCrossRef

56.

Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D: High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma. 1999, 34: 167-170.PubMedCrossRef

57.

Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, Joshi R, Mackie PH, Douglas ID, Bowcock SJ, Catovsky D: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003, 82: 759-765. 10.1007/s00277-003-0710-5.PubMedCrossRef

58.

Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ: Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008, 22: 2048-2053. 10.1038/leu.2008.214.PubMedCrossRef

59.

Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ: Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009, 23: 1779-1789. 10.1038/leu.2009.133.PubMedCentralPubMedCrossRef

60.

Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD: Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007, 48: 2412-2417. 10.1080/10428190701724801.PubMedCrossRef

61.

Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L: Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011, 52: 1055-1065. 10.3109/10428194.2011.562572.PubMedCrossRef

62.

Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Paz RN, Bernal-Corzo C, Ale-Ali A, James DF, Kipps TJ: Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience. ASH Annual Meeting Abstracts. 2010, 116: 4638-

63.

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009, 27: 6012-6018. 10.1200/JCO.2009.22.6944.PubMedCentralPubMedCrossRef

64.

Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Larson R, Kipps TJ, Leblond V, Milligan D, Janssens A: Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. ASH Annual Meeting Abstracts. 2010, 116: 58-

65.

Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA: Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. ASH Annual Meeting Abstracts. 2010, 116: 2456-

66.

Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC: Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica. 2012, 97: 423-427. 10.3324/haematol.2011.047324.PubMedCentralPubMedCrossRef

67.

Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ: Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. ASH Annual Meeting Abstracts. 2011, 118: 3910-

68.

Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P: Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration. ASH Annual Meeting Abstracts. 2010, 116: 1396-

69.

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney D, Xiong H, Cui Y, Busman T, Enschede S: An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2009, 114: 883-

70.

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012, 30: 488-496. 10.1200/JCO.2011.34.7898.PubMedCrossRef

71.

Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S, Humerickhouse R: Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 3904-

72.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR: 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009, 27: 5208-5212. 10.1200/JCO.2009.22.5748.PubMedCrossRef

73.

Balakrishnan K, Burger JA, Wierda WG, Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009, 113: 149-153. 10.1182/blood-2008-02-138560.PubMedCentralPubMedCrossRef

74.

O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009, 113: 299-305.PubMedCrossRef

75.

Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen JB, Orum H, Wissenbach M: The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia. 2011, 25: 638-647. 10.1038/leu.2010.322.PubMedCrossRef

76.

Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL: The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011, 118: 3603-3612. 10.1182/blood-2011-05-352492.PubMedCrossRef

77.

Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SE, Lannutti B: CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 55-

78.

Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, Schreeder MT, Barrientos JC, Wagner-Johnston ND, Boyd T: A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 1787-

79.

Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, Rockich K, Egile C, Kelly A, Xu Y, Lager J, Awan FT: Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. ASH Annual Meeting Abstracts. 2011, 118: 2683-

80.

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012, 119: 2590-2594. 10.1182/blood-2011-11-390989.PubMedCrossRef

81.

Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2011, 29: 6508-

82.

O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ: The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. ASH Annual Meeting Abstracts. 2011, 118: 983-

83.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010, 115: 2578-2585. 10.1182/blood-2009-08-236471.PubMedCentralPubMedCrossRef

84.

Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA: B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009, 114: 1029-1037. 10.1182/blood-2009-03-212837.PubMedCrossRef

85.

Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA: Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012, 26: 1576-1583. 10.1038/leu.2012.24.PubMedCrossRef

86.

Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P: Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011, 17: 2977-2986. 10.1158/1078-0432.CCR-10-2879.PubMedCentralPubMedCrossRef

87.

Al-Ameri AM, Badoux X, Ferrajoli A, Wierda WG, Fayad L, Estrov Z, Bickel S, Keating MJ, O'Brien S: Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 4488-

88.

Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D: A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2011, 118: 2858-

89.

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C: Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011, 117: 1516-1521. 10.1182/blood-2010-09-308775.PubMedCrossRef

90.

Dreger P, Dohner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M: Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood. 2012, 119: 4851-4859. 10.1182/blood-2011-09-378505.PubMedCrossRef

91.

Caballero D, Garcia-Marco JA, Martino R, Mateos V, Ribera JM, Sarra J, Leon A, Sanz G, de la Serna J, Cabrera R: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res. 2005, 11: 7757-7763. 10.1158/1078-0432.CCR-05-0941.PubMedCrossRef

92.

Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005, 23: 3433-3438. 10.1200/JCO.2005.04.531.PubMedCrossRef

93.

Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005, 23: 5788-5794. 10.1200/JCO.2005.03.962.PubMedCrossRef

94.

Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000, 25: 717-722. 10.1038/sj.bmt.1702237.PubMedCrossRef

95.

Dreger P: Allotransplantation for chronic lymphocytic leukemia. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009, 1: 602-609.CrossRef

96.

Delgado J, Milligan DW, Dreger P: Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood. 2009, 114: 2581-2588. 10.1182/blood-2009-05-206821.PubMedCrossRef

97.

Kharfan-Dabaja MA, Bazarbachi A: Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer control: journal of the Moffitt Cancer Center. 2012, 19: 68-75.

98.

Hsu Y, Saliba RM, Okoroji G-J, o'Brien S, Ferrajoli A, Abruzzo LV, Champlin R, Keating MJ, Khouri IF: Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion. ASH Annual Meeting Abstracts. 2011, 118: 4123-

99.

Milani C, Castillo J: Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009, 11: 200-207.PubMed

100.

Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA: Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012, 18: 1395-1403. 10.1158/1078-0432.CCR-11-0850.PubMedCrossRef

101.

Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B: The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-kappaB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol. 2011, 38: 1683-1694.PubMed

102.

Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res. 2009, 15: 2739-2746. 10.1158/1078-0432.CCR-08-1694.PubMedCrossRef

103.

Robak T, Robak P, Smolewski P: TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009, 10: 1383-1390.PubMed

104.

Furman RR, Forero-Torres A, Shustov A, Drachman JG: A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010, 51: 228-235. 10.3109/10428190903440946.PubMedCrossRef

105.

Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S: Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012, in press

106.

Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP: The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leuk Lymphoma. 2012, 53: 1367-1375. 10.3109/10428194.2011.647310.PubMedCrossRef

107.

Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH, Goettl VM, Zhang X, Jarjoura D, Raymond CA: 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010, 116: 45-53. 10.1182/blood-2010-01-263756.PubMedCentralPubMedCrossRef

108.

Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5.PubMedCentralPubMedCrossRef

109.

Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C: Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012, 53: 218-224. 10.3109/10428194.2011.610012.PubMedCrossRef

110.

Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. Journal of hematology & oncology. 2011, 4: 16-10.1186/1756-8722-4-16.CrossRef

111.

Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C: A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol. 2009, 88: 221-227. 10.1007/s00277-008-0582-9.PubMedCrossRef

Title: Therapeutic advancement of chronic lymphocytic leukemia
Authors: Kang Lu
Xin Wang
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-5-55

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia

A novel monoclonal antibody of human stem cell factor inhibits umbilical cord blood stem cell ex vivo expansion

Novel human polyomaviruses, Merkel cell polyomavirus and human polyomavirus 9, in Japanese chronic lymphocytic leukemia cases

Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis

Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity

Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

Keynote webinar | Spotlight on antibody–drug conjugates in cancer